The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Commentary|Videos|March 3, 2026
Dr Pearson on Daily Applications of AI in Clinical Practice
Author(s)Alexander T. Pearson, MD, PhD
Fact checked by: Kyle Doherty
Alexander T. Pearson, MD, PhD, discusses how he uses AI in his current daily practice.
Advertisement
Alexander T. Pearson, MD, PhD, outlines AI tools that he uses in his current practice, including ambient dictation. He emphasizes how this technology enables him to focus on interactions with patients rather than meticulous note taking while still being able to achieve digestible and accurate notes of the visit.
Advertisement
Related to this article
Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Five Under 5: Top Oncology Videos for the Week of 8/31/26
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5